VENLO, the Netherlands--(BUSINESS WIRE)--Jul 31, 2018--QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) announced results of operations for the second quarter and first half of 2018, delivering on the target for net sales growth and exceeding on adjusted earnings per share while driving the expansion of its Sample to Insight portfolio of molecular testing solutions.
“Our results for the second quarter of 2018 demonstrated a solid performance and further progress toward our goals for an exciting year of growth,” said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “We are on track to achieve our targets for higher sales and adjusted earnings while building momentum across our Sample to Insight portfolio and creating value for our customers and stakeholders.”
Please find the full press release here
View source version on businesswire.com:https://www.businesswire.com/news/home/20180731005893/en/
CONTACT: QIAGEN N.V.
Vice President Corporate Communications and Investor Relations
+49 2103 29 11711 and +1 240 686 2222
Dr. Sarah Fakih
Director Investor Relations
+49 2103 29 11457
Dr. Thomas Theuringer
Senior Director Public Relations and Digital Communications
+49 2103 29 11826 and +1 240 686 7425
KEYWORD: UNITED STATES EUROPE NORTH AMERICA NETHERLANDS GERMANY NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY OTHER HEALTH
SOURCE: QIAGEN N.V.
Copyright Business Wire 2018.
PUB: 07/31/2018 04:05 PM/DISC: 07/31/2018 04:05 PM